MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag091

Медицинская библиотека · The oncologist · 2026

Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Safyan Rachael A, White Ruth A, Gonda Tamas A, Lee Shing M, Han Jiying, Kuriakose Nadine, Yamamoto Naomi K, Kugel Sita, Jamison Jacob K, Manji Gulam A, Schwartz Gary J, Oberstein Paul E, Bates Susan E

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

Epigenetic regulators represent a novel strategy to modulate the tumor immune microenvironment in pancreatic ductal adenocarcinoma (PDAC). In preclinical models, DNA hypomethylating agents enhance cytotoxic T-cell infiltration, synergize with PD-1 blockade, and improve survival when combined with immune checkpoint blockade. This single-institution, phase II study evaluated the safety, efficacy, and biomarkers of azacitidine plus pembrolizumab in patients with previously treated PDAC.

METHODS

Patients with locally advanced or metastatic PDAC after one prior regimen received 50 mg/m2 subcutaneous azacitidine on days 1-5 of a 28-day cycle, starting week 1, and pembrolizumab 200 mg intravenously every 3 weeks starting week 3. Baseline and on-treatment blood and tumor was collected for exploratory biomarker analysis.

RESULTS

Thirty-six patients enrolled between October 2017 and September 2021 (median age: 62.5 years); 34 were evaluable for safety; 31 for efficacy. Treatment was generally well-tolerated, with Grade 1-2 fatigue and diarrhea most common AEs. Three patients (9.7%) had a partial response, and the disease control rate was 35.5%. Median progression-free and overall survival was 1.51 and 4.83 months, respectively. Exploratory analysis suggested higher baseline CD8+ T cells and lower tumor Ki-67 was associated with response, whereas low baseline CD8+ T cell and Granzyme B infiltration correlated with higher exponential tumor growth rate. PD-L1 and CD68 expression were not predictive of benefit.

CONCLUSION

Azacitidine plus pembrolizumab demonstrated limited clinical activity in second line, locally advanced or metastatic PDAC. Biomarker analysis suggests higher baseline CD8+ T-cell infiltration and lower proliferative index may identify patients more likely to benefit. Clinical trial registration number: NCT03264404.

Для цитирования: Safyan Rachael A, White Ruth A, Gonda Tamas A, Lee Shing M, Han Jiying, Kuriakose Nadine, Yamamoto Naomi K, Kugel Sita, Jamison Jacob K, Manji Gulam A, Schwartz Gary J, Oberstein Paul E, Bates Susan E. Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag091.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.